专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08346083B2 Bandwidth allocation method and passive optical network system 有权
标题翻译：带宽分配方法和无源光网络系统
公开(公告)号：US08346083B2
公开(公告)日：2013-01-01
申请号：US12866356
申请日：2009-02-17
申请人： Daisuke Murayama , Noriyuki Oota , Noriki Miki
发明人： Daisuke Murayama , Noriyuki Oota , Noriki Miki
IPC分类号： H04J14/00
CPC分类号： H04Q11/0067 , H04L47/10 , H04L47/263 , H04L47/70 , H04L47/722 , H04L47/762 , H04Q2011/0064
摘要： An optical line terminal calculates a requirement threshold for each optical subscriber unit based on a difference between the time average allocated bandwidth of each optical subscriber unit and the target bandwidth, and notifies a corresponding optical subscriber unit of the calculated requirement threshold. The corresponding optical subscriber unit then notifies, based on the data amount accumulated in a buffer, the optical line terminal of a data amount, as a transmission requirement, up to a data separation that is less or equal to the notified requirement threshold and in which a maximum transmission amount can be transmitted. The optical line terminal then notifies the corresponding optical subscriber unit of a transmission permission amount in which the data equal to the transmission requirement of which the optical line terminal is notified can be transmitted. The corresponding optical subscriber unit then transmits the data amount corresponding to the transmission permission amount.
摘要翻译：光线路终端基于每个光用户单元的时间平均分配带宽与目标带宽之间的差异来计算每个光用户单元的需求阈值，并将相应的光用户单元通知所计算的需求阈值。相应的光用户单元然后根据缓冲器中存储的数据量将数据量的光线路终端作为发送要求通知直到小于或等于所通知的需求阈值的数据分离，其中可以发送最大传输量。然后，光线路终端向相应的光用户单元通知能够发送与通过光线路终端通知的发送要求相等的数据的发送许可量。然后相应的光用户单元发送与发送允许量对应的数据量。

2. 发明申请

US20100322634A1 BANDWIDTH ALLOCATION METHOD AND PASSIVE OPTICAL NETWORK SYSTEM 有权
标题翻译：带宽分配方法和被动光网络系统
公开(公告)号：US20100322634A1
公开(公告)日：2010-12-23
申请号：US12866356
申请日：2009-02-17
申请人： Daisuke Murayama , Noriyuki Oota , Noriki Miki
发明人： Daisuke Murayama , Noriyuki Oota , Noriki Miki
IPC分类号： H04J14/08
CPC分类号： H04Q11/0067 , H04L47/10 , H04L47/263 , H04L47/70 , H04L47/722 , H04L47/762 , H04Q2011/0064
摘要： An optical line terminal calculates a requirement threshold for each optical subscriber unit based on a difference between the time average allocated bandwidth of each optical subscriber unit and the target bandwidth, and notifies a corresponding optical subscriber unit of the calculated requirement threshold. The corresponding optical subscriber unit then notifies, based on the data amount accumulated in a buffer, the optical line terminal of a data amount, as a transmission requirement, up to a data separation that is less or equal to the notified requirement threshold and in which a maximum transmission amount can be transmitted. The optical line terminal then notifies the corresponding optical subscriber unit of a transmission permission amount in which the data equal to the transmission requirement of which the optical line terminal is notified can be transmitted. The corresponding optical subscriber unit then transmits the data amount corresponding to the transmission permission amount.
摘要翻译：光线路终端基于每个光用户单元的时间平均分配带宽与目标带宽之间的差异来计算每个光用户单元的需求阈值，并将相应的光用户单元通知所计算的需求阈值。相应的光用户单元然后根据缓冲器中存储的数据量将数据量的光线路终端作为发送要求通知直到小于或等于所通知的需求阈值的数据分离，其中可以发送最大传输量。然后，光线路终端向相应的光用户单元通知能够发送与通过光线路终端通知的发送要求相等的数据的发送许可量。然后相应的光用户单元发送与发送允许量对应的数据量。

3. 发明申请

US20100144807A1 PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE 审中-公开
标题翻译：用于改性释放的药物组合物
公开(公告)号：US20100144807A1
公开(公告)日：2010-06-10
申请号：US12568313
申请日：2009-09-28
申请人： Yuuki Takaishi , Yutaka Takahashi , Takashi Nishizato , Daisuke Murayama , Emiko Murayama , Soichiro Nakamura , Kazuhiro Sako
发明人： Yuuki Takaishi , Yutaka Takahashi , Takashi Nishizato , Daisuke Murayama , Emiko Murayama , Soichiro Nakamura , Kazuhiro Sako
IPC分类号： A61K31/426 , A61P3/08
CPC分类号： A61K31/426 , A61K9/2009 , A61K9/2013 , A61K9/2031 , A61K9/2054 , A61K9/2095 , A61K9/2853 , A61K9/2866
摘要： A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 5 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed.
摘要翻译：一种用于改性释放的药物组合物，其包含（1）（R）-2-（2-氨基噻唑-4-基）-4' - [2 - [（2-羟基-2-苯乙基）氨基]乙基]乙酰苯胺，或其药学上可接受的盐，（2）至少一种添加剂，其确保水渗透到药物组合物中并且具有使得溶解1g添加剂所需的水的体积为5mL或更小的溶解度，（3）公开了在25℃下5％水溶液下的平均分子量为约100,000以上或粘度为12mPa·s以上的水凝胶形成性聚合物。

4. 发明申请

US20110065746A1 COMPOSITION OF SOLIFENACIN OR SALT THEREOF FOR USE IN SOLID FORMULATION 审中-公开
标题翻译：用于固体配方中的固体或盐的组合物
公开(公告)号：US20110065746A1
公开(公告)日：2011-03-17
申请号：US12950492
申请日：2010-11-19
申请人： Akio SUGIHARA , Takehiko Yasuji , Katsuhiro Masaki , Daisuke Murayama
发明人： Akio SUGIHARA , Takehiko Yasuji , Katsuhiro Masaki , Daisuke Murayama
IPC分类号： A61K31/439 , C07D453/02 , A61P13/10 , A61P13/00 , A61P11/00 , A61P11/06 , A61P11/02
CPC分类号： C07D453/02 , A61K9/2031 , A61K31/439
摘要： A solid pharmaceutical preparation of solifenacin or a salt thereof, the preparation being stable and inhibited from decomposing with time when supplied to clinical fields. In a pharmaceutical preparation containing solifenacin or a salt thereof, the compound in an amorphous form was revealed to be causative of cardinal-drug decomposition with time. The composition for a solid pharmaceutical preparation of solifenacin or a salt thereof contains solifenacin or its salt each in a crystalline from, and the content provided are: a process for producing the composition; and a medicinal composition for solid pharmaceutical preparations which contains solifenacin and an amorphization inhibitor.
摘要翻译：索利诺辛或其盐的固体药物制剂，当供应到临床领域时，该制剂是稳定的并且被抑制随时间分解。在含有索非那新或其盐的药物制剂中，显示无定形形式的化合物随着时间的推移与原药分解有关。索非塞星或其盐的固体药物制剂的组合物含有solifenacin或其盐，各自为结晶，所提供的内容为：制备组合物的方法; 以及含有solifenacin和非晶化抑制剂的固体药物制剂用药物组合物。

5. 发明授权

US08039482B2 Composition of solifenacin or salt thereof for use in solid formulation 有权
标题翻译：用于固体制剂的索非那新或其盐的组合物
公开(公告)号：US08039482B2
公开(公告)日：2011-10-18
申请号：US10594127
申请日：2005-03-24
申请人： Akio Sugihara , Takehiko Yasuji , Katsuhiro Masaki , Daisuke Murayama
发明人： Akio Sugihara , Takehiko Yasuji , Katsuhiro Masaki , Daisuke Murayama
IPC分类号： C07D453/02 , C07D453/04 , A01N43/90
CPC分类号： C07D453/02 , A61K9/2031 , A61K31/439
摘要： A solid pharmaceutical preparation of solifenacin or a salt thereof, the preparation being stable and inhibited from decomposing with time when supplied to clinical fields. In a pharmaceutical preparation containing solifenacin or a salt thereof, the compound in an amorphous form was revealed to be causative of cardinal-drug decomposition with time. The composition for a solid pharmaceutical preparation of solifenacin or a salt thereof contains solifenacin or its salt each in a crystalline from, and the content provided are: a process for producing the composition; and a medicinal composition for solid pharmaceutical preparations which contains solifenacin and an amorphization inhibitor.
摘要翻译：索利诺辛或其盐的固体药物制剂，当供应到临床领域时，该制剂是稳定的并且被抑制随时间分解。在含有索非那新或其盐的药物制剂中，显示无定形形式的化合物随着时间的推移与原药分解有关。索非塞星或其盐的固体药物制剂的组合物含有solifenacin或其盐，各自为结晶，所提供的内容为：制备组合物的方法; 以及含有solifenacin和非晶化抑制剂的固体药物制剂用药物组合物。

6. 发明申请

US20080039516A1 Composition of Solifenacin or Salt Thereof for Use in Solid Formulation 有权
标题翻译：索非那新或其盐的组合用于固体制剂
公开(公告)号：US20080039516A1
公开(公告)日：2008-02-14
申请号：US10594127
申请日：2005-03-24
申请人： Akio Sugihara , Takehiko Yasuji , Katsuhiro Masaki , Daisuke Murayama
发明人： Akio Sugihara , Takehiko Yasuji , Katsuhiro Masaki , Daisuke Murayama
IPC分类号： A61K31/40 , A61P43/00 , C07D453/02
CPC分类号： C07D453/02 , A61K9/2031 , A61K31/439
摘要： A solid pharmaceutical preparation of solifenacin or a salt thereof, the preparation being stable and inhibited from decomposing with time when supplied to clinical fields. In a pharmaceutical preparation containing solifenacin or a salt thereof, the compound in an amorphous form was revealed to be causative of cardinal-drug decomposition with time. The composition for a solid pharmaceutical preparation of solifenacin or a salt thereof contains solifenacin or its salt each in a crystalline from, and the content provided are: a process for producing the composition; and a medicinal composition for solid pharmaceutical preparations which contains solifenacin and an amorphization inhibitor.
摘要翻译：索利诺辛或其盐的固体药物制剂，当供应到临床领域时，该制剂是稳定的并且被抑制随时间分解。在含有索非那新或其盐的药物制剂中，显示无定形形式的化合物随着时间的推移与原药分解有关。索非塞星或其盐的固体药物制剂的组合物含有solifenacin或其盐，各自为结晶，所提供的内容为：制备组合物的方法; 以及含有solifenacin和非晶化抑制剂的固体药物制剂用药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式